Feb 08th 2013 - Edison Investment Research today published a report on quickview entitled "Fear Of The Unknown". In summary, the report says:
Nektar’s pipeline features several late-stage assets. Naloxegol for opioid-induced constipation (OIC) currently gets the most attention. Positive Phase III data are already in hand, but long-term cardiovascular (CV) safety concerns persist. Given recent FDA precedence, a long-term CV outcomes study may be required, which by itself should make investors cautious on the stock at these levels.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »
